Investors Take Flight After Bluebird Bio’s Sickle Cell Delay
Stock Plunges By 25% After Setback
Executive Summary
Bluebird’s first two gene therapies are on the market, but a new delay to its biggest hope, the sickle cell disease candidate lovo-cell, has spooked investors.
You may also be interested in...
No Pain, Lots To Gain: Vertex Looks For Non-Opioid Drug Breakthrough
Vertex is closing in on annual revenues of $10bn from its cystic fibrosis drugs, but non-opioid pain therapy candidate VX-548 could open up a whole new blockbuster revenue stream if Phase III studies go to plan.
Bluebird Files Sickle Cell Gene Therapy, Just Weeks Behind Vertex
The company is seeking a priority review from the US Food and Drug Administration.
ICER Says Gene Therapies For Sickle Cell Likely To Improve Lives, But Points To Uncertainties
The drug pricing watchdog said improvement to patients’ quality and length of life from lovo-cel and exa-cel were likely, but noted ongoing uncertainty around durability and toxicity concerns.